Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.85 |
| ▸ | JAK2 | O60674 | 1/20 | 0.85 |
| ▸ | LCK | P06239 | 1/20 | 0.85 |
| ▸ | YES1 | P07947 | 1/20 | 0.85 |
| ▸ | LYN | P07948 | 1/20 | 0.85 |
| ▸ | FGR | P09769 | 1/20 | 0.85 |
| ▸ | SRC | P12931 | 1/20 | 0.85 |
| ▸ | PRKCA | P17252 | 1/20 | 0.85 |
| ▸ | FLT3 | P36888 | 1/20 | 0.85 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.85 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.85 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL15255188 | 0.93 | SYK (0.93) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL900582 | 0.92 | SYK (1.00) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL899872 | 0.92 | SYK (1.00) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL14977351 | 0.92 | SYK (1.00) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL1353814 | 0.92 | SYK (1.00) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL1352147 | 0.92 | SYK (1.00) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL13624896 | 0.92 | SYK (1.00) | SYKKCNH2JAK2LCKYES1 | |
| Hydrochloric Acid SCHEMBL900878 | 0.91 | SYK (0.98) | SYKKCNH2JAK2LCKYES1 | |
| Hydrochloric Acid SCHEMBL29392320 | 0.91 | SYK (0.98) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL2627078 | 0.91 | SYK (0.86) | SYKKCNH2JAK2LCKYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579320-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160009694-A1 | CYCLOHEXANEDIAMINE COMPOUNDS AND METHODS FOR THEIR PREPARATION | ALEXION PHARMACEUTICALS, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-10-22 | — | — | US | disclosed |
| US-8952027-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130252917-A1 | COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130244963-A1 | COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130165431-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8349860-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8318755-B2 | Inhibitors of SYK and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297595-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885KCNH2 2494/4885JAK2 4/4885 |
| US-20130252917-A1 | COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | BCL9, BCL9L, MCL1 | SYK 101/4885KCNH2 2098/4885JAK2 137/4885 |
| US-20130244963-A1 | COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE | SYK, BCL9L, BCL9 | SYK 1/4885KCNH2 474/4885JAK2 11/4885 |
| US-20130165431-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885KCNH2 2494/4885JAK2 4/4885 |
| US-20120130073-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885KCNH2 2494/4885JAK2 4/4885 |
| US-20160009694-A1 | CYCLOHEXANEDIAMINE COMPOUNDS AND METHODS FOR THEIR PREPARATION | SYK, BTK, LCK | SYK 1/4885KCNH2 2051/4885JAK2 86/4885 |
| US-20120101275-A1 | INHIBITORS OF SYK AND JAK PROTEIN KINASES | SYK, BTK, JAK1 | SYK 1/4885KCNH2 2494/4885JAK2 4/4885 |
| US-20100048567-A1 | Inhibitors of syk and JAK protein kinases | SYK, BTK, JAK1 | SYK 1/4885KCNH2 2494/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.